SIGN UP
LOG IN
MARKET
ABEO
ABEO
Abeona Therapeut
NASDAQ
7.57
-0.36
-4.54%
Opening 12:15 04/18 EDT
OPEN
7.94
PREV CLOSE
7.93
HIGH
8.17
LOW
7.55
VOLUME
117.03K
TURNOVER
0
52 WEEK HIGH
9.01
52 WEEK LOW
2.730
MARKET CAP
207.08M
P/E (TTM)
-2.9868
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ABEO last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at ABEO last week (0401-0405)?
Weekly Report · 04/08 11:22
ABEONA THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/01 12:30
Weekly Report: what happened at ABEO last week (0325-0329)?
Weekly Report · 04/01 11:19
Weekly Report: what happened at ABEO last week (0318-0322)?
Weekly Report · 03/25 11:22
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's, Q4 earnings came out today. Taysha Gene Therapies shares moved upwards by 29.36%.
Benzinga · 03/19 21:34
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
Abeona Therapeutics reported earnings per share of -64 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -47 cents. Abeona TherAPEutics is a biotechnology company.
Investorplace · 03/19 10:53
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility
Abeona Therapeutics shares were down 13% to $7.50. The company said the FDA completed a pre-license inspection of its Cleveland, Ohio, manufacturing facility. The stock hit its 52-week high of $9.01 on March 6. Abeona said the inspection was in relation to its Biologics License Application for pz-cel.
Dow Jones · 03/18 14:24
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Webull offers Abeona Therapeutics Inc stock information, including NASDAQ: ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.